Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Garp1on Dec 04, 2022 6:30am
415 Views
Post# 35149215

How long must we wait

How long must we wait
IMO, Paul was forced to come out with this announcement because of the new brokerage firm reports and the fact that he had told the market that news was coming in December. I believe He would of continued to hide the facts,if the brokerage firms had not produced any report. I also think that has a CEO and based on the information he told the markets he should have refrained form pursuing or even suggesting a revised trial plan whithout at least demonstrating the viability of such an option. A post-mortum analysis should have been proposed by Paul before even suggesting any continuance of the trial and he should have implemented all necessary cost cutting measures and strategic decisions to demonstrate is committement to protect the business, the shareholder  and also indicated to the market that he was taking all measures required to recover and grow from this. This should have been done at the same time as the announcement. One must question at this stage if Paul represents the type of CEO that Thera needs right now.
<< Previous
Bullboard Posts
Next >>